Update on primary mucosal melanoma - 16/07/14
, Julie Bray, CNP b, Yoon K. Cohen, DO a, Joshua Arbesman, MD a, Julian Kim, MD c, Henry B. Koon, MD b, Kord Honda, MD a, Kevin D. Cooper, MD a, Meg R. Gerstenblith, MD aAbstract |
Mucosal melanomas are aggressive cancers of mucosal surfaces with clinical and pathologic characteristics distinct from cutaneous melanomas, warranting different staging systems and treatment approaches. Surgical resection is performed frequently for the primary tumor, although the utility of lymph node surgery and radiation therapy is not established. Therapies targeted against C-KIT activating mutations, identified in many mucosal melanomas, are emerging as promising treatments.
Il testo completo di questo articolo è disponibile in PDF.Key words : anorectal mucosal melanoma, C-KIT inhibitors, clinical characteristics, mucosal melanoma of the head and neck, pathology, urinary tract melanoma, vulvar and vaginal mucosal melanoma, treatment
Abbreviations used : AJCC, APR, CM, CSD, C-KIT, DSS, MM, MMP, MMU, MMAR, MMHN, MMVV, OR, OS, RT, SEER, SLNB, TNM, WLE
Mappa
| Funding sources: None. |
|
| Dr Gerstenblith is an investigator for and has received grants from the Dermatology Foundation and the Char and Chuck Fowler Family Foundation. Ms Bray is a speaker and has received honoraria from Bristol Myers Squibb. Dr Arbesman has received other financial benefits from Elsevier. |
Vol 71 - N° 2
P. 366-375 - agosto 2014 Ritorno al numero
Articolo precedente
- Skin cancer in organ transplant recipients: More than the immune system
- Lee Wheless, Sarah Jacks, Kathryn Anne Mooneyham Potter, Brian C. Leach, Joel Cook
- Munchausen syndrome and Munchausen syndrome by proxy in dermatology
- Alan S. Boyd, Coleman Ritchie, Sunaina Likhari
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?